Ahs Hospital Corp

1. Takeda Pharmaceuticals U.S.A., Inc. $183,935 44 payments
2. OPKO Pharmaceuticals, LLC $130,381 2 payments
3. Eisai Inc. $90,653 16 payments
4. GlaxoSmithKline, LLC. $63,089 16 payments
5. Ascendis Pharma, Inc. $31,110 1 payment
6. Boehringer Ingelheim Pharmaceuticals, Inc. $27,460 2 payments
7. Amgen Inc. $23,933 5 payments
8. Biogen, Inc. $22,124 1 payment
9. Aurinia Pharma U.S., Inc. $16,553 5 payments
10. Ironwood Pharmaceuticals, Inc $11,500 2 payments

1. Safety and Efficacy Phase 3 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children $128,381 1 payment
2. A Multicenter, Randomized, Double-Blind Phase 2 Trial of Lenvatinib (E7080) in Subjects With 131I-Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 mg Daily Will Provide Comparable Efficacy to a 24-mg Starting Dose, But Have a Better Safety Profile $90,653 16 payments
3. EntyvioVedolizumab Long Term Study $49,465 7 payments
4. IL Believe $31,110 1 payment
5. A Phase 1B/2 Study of Tak-981 Plus Pembrolizumab to Evaluate the Safety, Tolerability, and Antitumor Activity of the Combination in Patients With Select Advanced Or Metastatic Solid Tumors $29,068 6 payments
6. Adult Allogeneic Expanded Adipose-derived Stem Cells eASC for the Treatment of Complex Perianal Fistulas in Patients With Crohn's Disease ADMIRE-CD-II $27,916 3 payments
7. A Randomized, Adaptive, Double-Blind, Placebo-Controlled, Parallel-Arm $23,653 3 payments
8. A Randomized, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of Vedolizumab Intravenous As Maintenance Therapy in Pediatric Subjects With Moderately to Severely Active Crohn's Disease Who Achieved Clinical Response Following Open-Label Vedolizumab Intravenous Therapy $22,490 6 payments
9. A Randomized, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of Vedolizumab Intravenous As Maintenance Therapy in Pediatric Subjects With Moderately to Severely Active Ulcerative Colitis Who Achieved Clinical Response Following Open-Label Vedolizumab Intravenous Therapy $22,490 6 payments
10. Study to Evaluate BIIB059 in Cutaneous Lupus Erythematosus (CLE) With or Without Systemic Lupus Erythematosus (SLE) $22,124 1 payment

1. Other $82,652 13 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.